ArticleAmerican journal of stem cells2013
The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis.
Article in American journal of stem cells, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Neural Stem Cells in Multiple Sclerosis: A Comprehensive Review of Preclinical and Clinical Evidence for CNS Repair and Translational Hurdles.Applied biochemistry and biotechnology · 2026Review
- Primary Progressive Multiple Sclerosis: New Therapeutic Approaches.Neuropsychopharmacology reports · 2025Review
- Role and Function of Mesenchymal Stem Cells on Fibroblast in Cutaneous Wound Healing.Biomedicines · 2022Review
- A cell-based drug delivery platform for treating central nervous system inflammation.Journal of molecular medicine (Berlin, Germany) · 2021Article
- Burns Impair Blood-Brain Barrier and Mesenchymal Stem Cells Can Reverse the Process in Mice.Frontiers in immunology · 2020Article
- Genetically modified hematopoietic stem/progenitor cells that produce IL-10-secreting regulatory T cells.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Transdifferentiation of human adipose-derived mesenchymal stem cells into oligodendrocyte progenitor cells.Iranian journal of neurology · 2018Article
- Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality?Stem cell research & therapy · 2016Review
- Stepping back to move forward: a current review of iPSCs in the fight against Alzheimer's disease.American journal of stem cells · 2016Review
- Stem Cells Therapy in Multiple Sclerosis - A New Hope for Progressive Forms.Journal of stem cells & regenerative medicine · 2016Article
- The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies.Advanced biomedical research · 2016Review
- Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II).BMJ open · 2015Article
- Transplantation of human adipose-derived stem cells enhances remyelination in lysolecithin-induced focal demyelination of rat spinal cord.Molecular biotechnology · 2014Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article examines the current use and future implications of stem cell therapy in treating Multiple Sclerosis (MS). MS is the most common neurological disease in young adults, affecting approximately two million people worldwide. Currently there is no cure for MS. The standard treatment of MS involves disease-modifying drugs, which work to alleviate the symptoms of MS. However, these drugs carry adverse side effects and are ineffective in preventing disease progression in many MS patients. Hematopoietic stem cell transplantation (HSCT) was first used in 1995 to treat patients with severe rapidly progressing MS. The HSCT treatment protocol has evolved into a less intense conditioning regimen that is currently demonstrating efficacy in treating patients with variable disease severity-with best results in early-stage rapidly progressing MS patients with active CNS inflammation. Mesenchymal stem cell therapy (MSCT) is an experimental stem cell therapy currently undergoing clinical trials. Animal models and early clinical trials have shown promise that MSCT might be a low risk treatment to precipitate neuroregeneration and immunomodulation in MS patients. Specifically, neuroprogenitor and placental-derived mesenchymal stem cells offer the best hope for a practical treatment for MS. Stem cell therapy, and perhaps a combinatorial therapeutic approach, holds promise for a better treatment for MS.
Indexed as
Identifiers
23862098PMC3708509W51349150What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.